270 related articles for article (PubMed ID: 23930849)
21. Immunocytochemical analysis of glucose transporter protein-1 (GLUT-1) in typical, brain invasive, atypical and anaplastic meningioma.
van de Nes JA; Griewank KG; Schmid KW; Grabellus F
Neuropathology; 2015 Feb; 35(1):24-36. PubMed ID: 25168354
[TBL] [Abstract][Full Text] [Related]
22. Benign and atypical meningioma metabolic signatures by high-resolution magic-angle spinning molecular profiling.
Monleón D; Morales JM; Gonzalez-Darder J; Talamantes F; Cortés O; Gil-Benso R; López-Ginés C; Cerdá-Nicolás M; Celda B
J Proteome Res; 2008 Jul; 7(7):2882-8. PubMed ID: 18507434
[TBL] [Abstract][Full Text] [Related]
23. Integrative genomic analysis identifies CCNB1 and CDC2 as candidate genes associated with meningioma recurrence.
Bie L; Zhao G; Ju Y; Zhang B
Cancer Genet; 2011 Oct; 204(10):536-40. PubMed ID: 22137483
[TBL] [Abstract][Full Text] [Related]
24. DNA microarray analysis identifies CKS2 and LEPR as potential markers of meningioma recurrence.
Menghi F; Orzan FN; Eoli M; Farinotti M; Maderna E; Pisati F; Bianchessi D; Valletta L; Lodrini S; Galli G; Anghileri E; Pellegatta S; Pollo B; Finocchiaro G
Oncologist; 2011; 16(10):1440-50. PubMed ID: 21948653
[TBL] [Abstract][Full Text] [Related]
25. Loss of histone H3K27me3 identifies a subset of meningiomas with increased risk of recurrence.
Katz LM; Hielscher T; Liechty B; Silverman J; Zagzag D; Sen R; Wu P; Golfinos JG; Reuss D; Neidert MC; Wirsching HG; Baumgarten P; Herold-Mende C; Wick W; Harter PN; Weller M; von Deimling A; Snuderl M; Sen C; Sahm F
Acta Neuropathol; 2018 Jun; 135(6):955-963. PubMed ID: 29627952
[TBL] [Abstract][Full Text] [Related]
26. Tumor grade-related NDRG2 gene expression in primary and recurrent intracranial meningiomas.
Skiriute D; Tamasauskas S; Asmoniene V; Saferis V; Skauminas K; Deltuva V; Tamasauskas A
J Neurooncol; 2011 Mar; 102(1):89-94. PubMed ID: 20607352
[TBL] [Abstract][Full Text] [Related]
27. [Methylation and expression analysis of p16(INK4a) and RB genes in meningiomas].
Chen MN; Mao Q; Liu YH; Mao BY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2004 Jun; 21(3):277-9. PubMed ID: 15192837
[TBL] [Abstract][Full Text] [Related]
28. miRNA-145 is downregulated in atypical and anaplastic meningiomas and negatively regulates motility and proliferation of meningioma cells.
Kliese N; Gobrecht P; Pachow D; Andrae N; Wilisch-Neumann A; Kirches E; Riek-Burchardt M; Angenstein F; Reifenberger G; Riemenschneider MJ; Meese E; Panayotova-Dimitrova D; Gutmann DH; Mawrin C
Oncogene; 2013 Sep; 32(39):4712-20. PubMed ID: 23108408
[TBL] [Abstract][Full Text] [Related]
29. Genomic and transcriptome analysis revealing an oncogenic functional module in meningiomas.
Chang X; Shi L; Gao F; Russin J; Zeng L; He S; Chen TC; Giannotta SL; Weisenberger DJ; Zada G; Wang K; Mack WJ
Neurosurg Focus; 2013 Dec; 35(6):E3. PubMed ID: 24289128
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical expression of SPARC is correlated with recurrence, survival and malignant potential in meningiomas.
Bozkurt SU; Ayan E; Bolukbasi F; Elmaci I; Pamir N; Sav A
APMIS; 2009 Sep; 117(9):651-9. PubMed ID: 19703125
[TBL] [Abstract][Full Text] [Related]
31. Comparative genomic hybridization analysis of genomic alterations in benign, atypical and anaplastic meningiomas.
Arslantas A; Artan S; Oner U; Durmaz R; Müslümanoğlu H; Atasoy MA; Başaran N; Tel E
Acta Neurol Belg; 2002 Jun; 102(2):53-62. PubMed ID: 12161900
[TBL] [Abstract][Full Text] [Related]
32. Correlation between histological grade and MIB-1 and p53 immunoreactivity in meningiomas.
Ozen O; Demirhan B; Altinörs N
Clin Neuropathol; 2005; 24(5):219-24. PubMed ID: 16167545
[TBL] [Abstract][Full Text] [Related]
33. Osteopontin predicts the behaviour of atypical meningioma.
Lin CK; Tsai WC; Lin YC; Hueng DY
Histopathology; 2012 Jan; 60(2):320-5. PubMed ID: 22211290
[TBL] [Abstract][Full Text] [Related]
34. Alterations of the tumor suppressor genes CDKN2A (p16(INK4a)), p14(ARF), CDKN2B (p15(INK4b)), and CDKN2C (p18(INK4c)) in atypical and anaplastic meningiomas.
Boström J; Meyer-Puttlitz B; Wolter M; Blaschke B; Weber RG; Lichter P; Ichimura K; Collins VP; Reifenberger G
Am J Pathol; 2001 Aug; 159(2):661-9. PubMed ID: 11485924
[TBL] [Abstract][Full Text] [Related]
35. Non-NF2 mutations have a key effect on inhibitory immune checkpoints and tumor pathogenesis in skull base meningiomas.
Hao S; Huang G; Feng J; Li D; Wang K; Wang L; Wu Z; Wan H; Zhang L; Zhang J
J Neurooncol; 2019 Aug; 144(1):11-20. PubMed ID: 31177425
[TBL] [Abstract][Full Text] [Related]
36. Aberrant DNA methylation of alternative promoter of DLC1 isoform 1 in meningiomas.
Bujko M; Kober P; Rusetska N; Wakuła M; Goryca K; Grecka E; Matyja E; Neska J; Mandat T; Bonicki W; Siedlecki JA
J Neurooncol; 2016 Dec; 130(3):473-484. PubMed ID: 27614886
[TBL] [Abstract][Full Text] [Related]
37. Detection of S100B, S100A6 and galectin-3 ligands in meningiomas as markers of aggressiveness.
Hancq S; Salmon I; Brotchi J; Gabius HJ; Heizmann CW; Kiss R; Decaestecker C
Int J Oncol; 2004 Nov; 25(5):1233-40. PubMed ID: 15492810
[TBL] [Abstract][Full Text] [Related]
38. Gene expression profiles of metabolic aggressiveness and tumor recurrence in benign meningioma.
Serna E; Morales JM; Mata M; Gonzalez-Darder J; San Miguel T; Gil-Benso R; Lopez-Gines C; Cerda-Nicolas M; Monleon D
PLoS One; 2013; 8(6):e67291. PubMed ID: 23840654
[TBL] [Abstract][Full Text] [Related]
39. Metabolic aggressiveness in benign meningiomas with chromosomal instabilities.
Monleón D; Morales JM; Gonzalez-Segura A; Gonzalez-Darder JM; Gil-Benso R; Cerdá-Nicolás M; López-Ginés C
Cancer Res; 2010 Nov; 70(21):8426-34. PubMed ID: 20861191
[TBL] [Abstract][Full Text] [Related]
40. Intracranial meningiomas, the VEGF-A pathway, and peritumoral brain oedema.
Nassehi D
Dan Med J; 2013 Apr; 60(4):B4626. PubMed ID: 23651727
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
